The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis [20]

Clinical and Experimental Dermatology

Volumn 30, Issue 5, 2005, Pages 600-602

  Yeung, C K ^a   Lam, L K ^a   Chan, H H ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; DICLOFENAC; GRISEOFULVIN; IMMUNOGLOBULIN; ORGANIC SOLVENT; PENICILLIN G; PHENOBARBITAL; PHENYTOIN;

ADULT; AGED; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; IMMUNOTHERAPY; LETTER; MALE; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SEPTIC SHOCK; STEROID THERAPY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 23044452819     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01863.x     Document Type: Letter

References (5)

1. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485-95.
2. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
3. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
4. Trent JT, Kirsner RS, Romanelli P et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. The University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
5. Prins C, Kerdel FA, Padilla RS et al. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.